1. Validation of a Scoring System for Predicting Malignancy in Patients Diagnosed with Atypical Ductal Hyperplasia Using an Ultrasound-Guided Core Needle Biopsy
- Author
-
Dong Young Noh, Nariya Cho, Jung Min Chang, Hyeong-Gon Moon, Jisun Kim, Hee Chul Shin, Soo Kyung Ahn, Eun Young Go, Wonshik Han, Jee Man You, In Ae Park, and Woo Kyung Moon
- Subjects
Diagnostic errors ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,medicine.diagnostic_test ,Breast hyperplasia ,business.industry ,Breast Hyperplasia ,Area under the curve ,Needle biopsy ,Malignancy ,medicine.disease ,Surgery ,Lesion ,Breast cancer ,Oncology ,Biopsy ,medicine ,Original Article ,Microcalcification ,Radiology ,Breast neoplasms ,medicine.symptom ,business - Abstract
Purpose: The need for surgical excision in patients with ultrasound-guided core needle biopsy (CNB)-diagnosed atypical ductal hyperplasia (ADH) remains an issue of debate. The present study sought to validate a scoring system (the U score, for underestimation) that we have previously developed for predicting malignancy in CNB-diagnosed ADH. Methods: The study prospectively enrolled 85 female patients with CNB-diagnosed ADH who underwent subsequent surgical excision. Underestimation was defined as a surgical specimen having malignant foci. Results: The overall underestimation rate was 37% (31/85). Multivariate analysis showed that a clinically palpable mass, microcalcification on imaging, size > 15 mm and a patient age of ≥ 50 years were independently associated with underestimation. When applied to the scoring system, the validation score was significant (p< 0.001; area under the curve, 0.852). No patient with a U score < 3.5 had an underestimated lesion. Conclusion: The present study successfully validated the efficacy of our scoring system for predicting malignancy in CNB-diagnosed ADH. A U score of ≤ 3.5 indicates that surgical excision may not be necessary.
- Published
- 2012